AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Amneal Pharmaceuticals, Inc. Class A Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00462PGH9
20.38▼ 0.10 (-0.49%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
20.48
Day's Range
19.93 – 20.49
52-Week Range
9.99 – 21.18
Volume
4.9M
Avg Volume
3.3M
Share Statistics
Shares Outstanding
Employees
8,500
Exchange
XNAS
Listed
2018-05-07
Share count as of July 31, 2026

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's Market Cap?
Amneal Pharmaceuticals, Inc. Class A Common Stock's Market Cap is $6.5B, based on as-reported figures from SEC (XBRL) filings.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's Enterprise Value?
Amneal Pharmaceuticals, Inc. Class A Common Stock's Enterprise Value is $9.0B, based on as-reported figures from SEC (XBRL) filings.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's Trailing P/E?
Amneal Pharmaceuticals, Inc. Class A Common Stock's Trailing P/E is 41.4×, based on as-reported figures from SEC (XBRL) filings.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's Price / Sales?
Amneal Pharmaceuticals, Inc. Class A Common Stock's Price / Sales is 2.1×, based on as-reported figures from SEC (XBRL) filings.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's EV / Revenue?
Amneal Pharmaceuticals, Inc. Class A Common Stock's EV / Revenue is 2.9×, based on as-reported figures from SEC (XBRL) filings.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's EV / EBITDA?
Amneal Pharmaceuticals, Inc. Class A Common Stock's EV / EBITDA is 13.7×, based on as-reported figures from SEC (XBRL) filings.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's Revenue (TTM)?
Amneal Pharmaceuticals, Inc. Class A Common Stock's Revenue (TTM) is $3.1B, based on as-reported figures from SEC (XBRL) filings.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's Net Income (TTM)?
Amneal Pharmaceuticals, Inc. Class A Common Stock's Net Income (TTM) is $157.4M, based on as-reported figures from SEC (XBRL) filings.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's EBITDA?
Amneal Pharmaceuticals, Inc. Class A Common Stock's EBITDA is $651.4M, based on as-reported figures from SEC (XBRL) filings.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's Diluted EPS (TTM)?
Amneal Pharmaceuticals, Inc. Class A Common Stock's Diluted EPS (TTM) is 0.49, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AMRXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Net revenue
YoY growth+9.9%+3.9%+11.5%+11.7%
Cost of goods sold
Gross profit
% of revenue42.0%44.3%36.5%34.9%
Selling, general and administrative
Research and development
Intellectual property legal development expenses
Acquisition costs——
Restructuring and other charges
Charges (credit) related to legal matters, net
Other operating income
Operating income
% of revenue16.3%19.6%13.8%9.0%
Other (expense) income:
Interest expense, net
Foreign exchange (loss) gain, net
Loss on refinancing
Increase in tax receivable agreement liability
Other income, net
Total other expense, net
Income before income taxes
Provision for income taxes
Net income
% of revenue8.7%10.8%6.1%2.3%
Less: Net income attributable to non-controlling interests
Net income attributable to Amneal Pharmaceuticals, Inc.
% of revenue7.2%8.6%4.3%0.3%
Net income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic (in dollars per share)
Diluted (in dollars per share)